navepegritide
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06079398)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetSupplementation
supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594507 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06732895 | Phase 2 | Dec 10, 2024 | Ascendis Pharma, Inc. |
| NCT06433557 | Phase 2 | Jul 26, 2024 | Ascendis Pharma, Inc. |
| NCT06079398 | Phase 2 | Dec 31, 2023 | Ascendis Pharma, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascendis Pharma, Inc. | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1